GlassScriptPhysician profile
Nohe Sebhatu
NPI 1093175226
$3,396.38
in general payments reported to CMS, 2019-2025
21 companies · $709 in 2025
The $709 reported for 2025 was more than what 80% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $634 · 2022: $694 · 2024: $1,360 · 2025: $709.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,060 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,060.34 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $750.55 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $418.17 | 2022-2025 | Sotyktu |
| Janssen Biotech, INC. | $332.26 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Genzyme Corporation | $309.70 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $259.30 | 2021-2024 | Dupixent, Libtayo |
| Incyte Corporation | $228.85 | 2022-2025 | Opzelura, Opzelura |
| Novartis Pharmaceuticals Corporation | $179.24 | 2021-2025 | |
| Ucb, INC. | $167.28 | 2021-2025 | Bimzelx |
| Amgen INC. | $165.27 | 2021-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $155.37 | 2021-2024 | |
| Pfizer INC. | $105.28 | 2021-2025 | |
| Leo Pharma INC. | $73.63 | 2024-2025 | Adbry |
| Kyowa Kirin, INC. | $50.03 | 2022-2025 | |
| Galderma Laboratories, L.P. | $44.47 | 2021-2025 | Nemluvio |
| Surgenex LLC | $42.85 | 2025 | Renograft, Surgraft, Pellograft |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verrica Pharmaceuticals INC. | $29.37 | 2025 | Ycanth |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.21 | 2024 | Cyltezo |
| Lilly USA, LLC | $20.72 | 2021 | |
| Arcutis Biotherapeutics, INC. | $19.65 | 2024 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $14.69 | 2021 | |
| Mayne Pharma Commercial LLC | $7.49 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nohe Sebhatu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.